- Home
- SPR vs MRUS Comparison
SPR vs MRUS Comparison
Compare SPR & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPR
- MRUS
- Stock Information
- Founded
- SPR 1927
- MRUS 2003
- Country
- SPR United States
- MRUS Netherlands
- Employees
- SPR N/A
- MRUS N/A
- Industry
- SPR Military/Government/Technical
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- SPR Industrials
- MRUS Health Care
- Exchange
- SPR Nasdaq
- MRUS Nasdaq
- Market Cap
- SPR 4.3B
- MRUS 4.1B
- IPO Year
- SPR 2006
- MRUS 2016
- Fundamental
- Price
- SPR $40.56
- MRUS $63.26
- Analyst Decision
- SPR Hold
- MRUS Strong Buy
- Analyst Count
- SPR 3
- MRUS 13
- Target Price
- SPR $37.42
- MRUS $88.54
- AVG Volume (30 Days)
- SPR 1.2M
- MRUS 603.8K
- Earning Date
- SPR 08-04-2025
- MRUS 07-31-2025
- Dividend Yield
- SPR N/A
- MRUS N/A
- EPS Growth
- SPR N/A
- MRUS N/A
- EPS
- SPR N/A
- MRUS N/A
- Revenue
- SPR $6,135,600,000.00
- MRUS $54,732,000.00
- Revenue This Year
- SPR $25.26
- MRUS $68.08
- Revenue Next Year
- SPR $14.17
- MRUS $0.09
- P/E Ratio
- SPR N/A
- MRUS N/A
- Revenue Growth
- SPR N/A
- MRUS 42.77
- 52 Week Low
- SPR $27.00
- MRUS $33.19
- 52 Week High
- SPR $41.14
- MRUS $63.43
- Technical
- Relative Strength Index (RSI)
- SPR 70.45
- MRUS 74.17
- Support Level
- SPR $40.27
- MRUS $54.09
- Resistance Level
- SPR $41.14
- MRUS $56.60
- Average True Range (ATR)
- SPR 0.76
- MRUS 1.97
- MACD
- SPR 0.16
- MRUS 0.77
- Stochastic Oscillator
- SPR 83.43
- MRUS 98.54
About SPR Spirit Aerosystems Holdings Inc.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005 to become the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue. The company plans to be acquired by and reintegrated into Boeing in mid-2025.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.